As of June 30, 2024, VYNE had cash, cash equivalents, restricted cash and marketable securities of $78.1 million. VYNE believes its cash, cash equivalents, restricted cash and marketable securities as of June 30, 2024 will be sufficient to fund its operations through the end of 2025.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYNE:
- VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- Vyne Therapeutics Inc (VYNE) Q2 Earnings Cheat Sheet
- VYNE Therapeutics announces granting of composition of matter patent for VYN202
- VYNE Therapeutics announces appointment of Banerjee as SVP
- VYNE Therapeutics to Participate in Leerink Partners Therapeutics Forum